Menu
Brit Mollenhauer is a neurologist with over 10 years clinical expertise in Parkinson’s disease and movement disorders.
She also has a degree in neurochemistry. After her studies in neuroscience at Harvard Medical School, Cambridge, USA she became head of translational research at the Paracelsus-Elena Klinik (PEKK), which is the largest hospital for movement disorders in Germany with 120 beds and more than 3000 patients per year.
Dr.Brit Mollenhauer has developed a study center for clinical trials and translational research with close collaborations with the Michael J. Fox Foundation for Parkinson’s Research; the clinic is one of the 7 European recruitment centers for the PPMI study.
The following 4 research products highlight our experience and qualifications as a Research Center of Excellence
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.
To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:
Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.
The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.
For additional information, please visit our billing page.
